Informations sur le produit
Nom :
Brivanib
Synonymes :
- (2R)-1-[4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol
- (2R)-1-[[4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-propanol
- 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)-
- Bms-540215
- Ptk787
- Vatalanib
Description :
Brivanib is a drug that belongs to the class of inhibitors. It was developed as an oral prodrug, brivanib alaninate, which is enzymatically cleaved to release brivanib. Brivanib inhibits human tyrosine kinases, including BCR-ABL and c-KIT. Brivanib has shown efficacy in inhibiting the growth of solid tumours in vivo. The molecular mechanisms underlying its anti-cancer properties are not fully understood, but it has been shown to inhibit cancer cell proliferation and induce apoptosis. Brivanib has also been shown to bind with high affinity to human plasma proteins and inhibit the binding of ADP-ribosylation factor (ARF) to its substrates.
Avis:
Nos produits sont destinés uniquement à un usage en laboratoire. Pour tout autre usage, veuillez nous contacter.
Marque:
Biosynth
Stockage à long terme :
Notes :
Propriétés chimiques
Masse moléculaire :
370.38 g/mol
Formule :
C19H19FN4O3
Degré de pureté :
Min. 95%
Couleur/Forme :
Powder
InChI :
InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
Code InChI :
InChIKey=WCWUXEGQKLTGDX-LLVKDONJSA-N
SMILES :
Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
MDL:
Point de fusion :
Point d'ébullition :
Point d'éclair :
Densité :
Concentration :
EINECS :
Merck :
Code SH :
